Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
This trial is active, not recruiting.
|Sponsor||Technische Universität München|
|Start date||August 2010|
|End date||December 2011|
|Trial size||50 participants|
|Trial identifier||NCT01198808, IBT-1|
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy.
It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.
Male or female participants from 18 years up to 90 years old.
Inclusion Criteria: - Histologically confirmed muscle-invasive urothelial carcinoma - Age > 18 years - Hemoglobin > 10g/dl - Signed Informed Consent - Karnofsky index < 70% Exclusion Criteria: - Clinically relevant second malignancy - Severe comorbidities (e.g. NYHA III, end-stage renal disease) - Chronic infectious disease (HIV, Tuberculosis) - Immunosupression - Severe psychiatric diseases - Blood donation in the last 4 weeks
|Official title||Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters|
|Principal investigator||Thomas Horn, MD|
Call for more information